Director dealing

/**/

RNS Number : 5626M EDX Medical Group PLC 23 December 2025  

  23 December 2025 EDX Medical Group plc · EDX AQSE: EDX ("EDX Medical" or the "Company")   Director dealing   CAMBRIDGE, UK: EDX Medical Group plc ("EDX Medical", the "Company" or the "Group"), which develops innovative digital diagnostic products and services for the personalised treatment for cancer, heart disease and infectious diseases, announces that it was informed yesterday that Dr Michael Hudson, Chief Executive Officer of the Company, purchased a total of 28,526 ordinary shares in the Company on 22 December 2025, at an average price per share of 10.57 pence. Dr Hudson now holds 20,600,000 ordinary shares in the Company.   The Company was also informed yesterday that Sebastian Hudson, a person closely associated with Dr Michael Hudson, purchased 22,500 shares on 22 December 2025, at an average price per share of 10.03 pence. Mr Hudson now holds 50,000 ordinary shares in the Company.   Taken together, Dr Hudson controls 20,650,000 ordinary shares, representing 5.34% of the Company's issued share capital.   This announcement is made in accordance with Article 19(1) of the EU Market Abuse Regulation as incorporated into UK law through the European Union (Withdrawal) Act 2018. The directors of the Company accept responsibility for the contents of this announcement.  

1  

Details of the person discharging managerial responsibilities / person closely associated  

a)  

Name  

Dr Michael Hudson

2  

Reason for the notification  

a)  

Position/status  

PDMR / Chief Executive Officer

b)  

Initial notification /Amendment  

Initial notification

3  

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  

a)  

Name  

EDX Medical Group PLC

b)  

LEI  

213800BZVJZTMCZ6DJ63

4  

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  

a)  

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

Identification code

ISIN: GB00BNDMJS47







b)  

Nature of the transaction    

Purchase of shares

c)  

Price(s) and volume(s)













Price

Volume







£0.1075

13,624







£0.1040

14,902















d)  

Aggregated information









- Aggregated volume

28,526







- Price

£0.1057







e)  

Date of the transaction    

2025-12-22

f)  

Place of the transaction    

AQSG - Aquis Growth Market (Equity)

 

1  

Details of the person discharging managerial responsibilities / person closely associated  

a)  

Name  

Sebastian Hudson

2  

Reason for the notification  

a)  

Position/status  

Person Closely Associated with Dr Michael Hudson

b)  

Initial notification /Amendment  

Initial notification

3  

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  

a)  

Name  

EDX Medical Group PLC

b)  

LEI  

213800BZVJZTMCZ6DJ63

4  

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  

a)  

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

Identification code

ISIN: GB00BNDMJS47







b)  

Nature of the transaction    

Purchase of shares

c)  

Price(s) and volume(s)













Price

Volume







£0.1020

7,425







£0.0995

15,075















d)  

Aggregated information









- Aggregated volume

22,500







- Price

£0.1003







e)  

Date of the transaction    

2025-12-22

f)  

Place of the transaction    

AQSG - Aquis Growth Market (Equity)

  ENDS   Contacts: 

EDX Medical Group plc



 



Dr Mike Hudson  (Chief Executive Officer)  

+44 (0)7812 345 301  

Oberon Capital



Nick Lovering (Corporate Adviser) Adam Pollock (Corporate Broking) Mike Seabrook (Corporate Broking)  

+44 (0)20 3179 5300

Media House International



Ramsay Smith     Gary McQueen

+44 (0)7788 414856 ramsay@mediahouse.co.uk   +44 (0)7834 694609 gary@mediahouse.co.uk  

IFC Advisory (Investor Relations)



Tim Metcalfe Graham Herring

+44 (0) 203 934 6632

    Notes to Editors:   About EDX Medical Group plc The EDX Medical Group plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX). EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson. By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally. EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services. www.edxmedical.com  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.  END  NEXFEEESEEISELE